Figure 5.

Plasma and organ distribution of aanti-miR-103/107-loaded LNP 3 after i.v. injection

(A) Expression analysis by real-time PCR of circulating anti-miRNA103/107 levels in blood of rats exposed to tMCAO and treated with anti-miR-103/107-loaded LNP 3 at different time intervals from reperfusion. In (B) are reported RHOD-1/Fluorescein fluorescent levels in different organs after i.v. injection of fluorescent LNP3. (A) Anti-microRNA levels are expressed as fold change of relative expression levels over the vehicle group, represented by ischemic rats treated with saline solution. (B) Quantification of fluorescence intensity on tissue sections at the level of the brain cortex, liver, heart and gastrocnemius muscle is expressed in terms of pixel intensity value. Pixels expressing rhodamine co-localizing with fluorescein were identified. Results are expressed in arbitrary units. Each column represents the mean ± SEM. Results of anti-microRNA expression were normalized with respect to U6 snRNA as internal control. n = 3–4 samples per each group. ∗p < 0.05 vs. other experimental groups.